Institute for International Research

Keynote Speakers

Ajaz Hussain, Ph.D.
Vice President, Biological Systems, R&D
Philip Morris International Global Services, USA

Rolf G. Werner, Ph.D.
Corporate Senior Vice President, Corporate Division Biopharmaceuticals
Boehringer Ingelheim GmbH, Germany

Thomas Schreitmueller, Ph.D.
Head, Health Authority Policy & Strategy Biologics
F. Hoffmann-La Roche Ltd., Switzerland

Why You Should Attend

China-based companies:
This is your chance to fill your information gaps without traveling outside of China! Learn from expert panels on critical topics including cell culture, cell line engineering, analytical method validation, process characterization, downstream processing, protein stability, disposables and more!

International companies:
China is considered one of the top emerging markets with a large amount of investment being made. This is your chance to understand China's current state of development in the bioprocessing field and find opportunities for collaborations in manufacturing, product or technology licensing, and outsourcing.

Special Discounted Hotel Rate

To book your room, contact Kathy Guo at Kathy.guo@westin.com or call +86-10-66068866.

LinkedIn Groups

Join the BioProcessing Professionals LinkedIn Group

Join the China Life Sciences Network LinkedIn Group

The Most Data-Rich Scientific and Technical Sessions to Improve Your Bioprocessing Capabilities

Establish capabilities in manufacturing biologics, biosimilars and vaccines, while gaining a strong knowledge of the emerging areas throughout the bioprocess value-chain, including:

• Developing a Biopharmaceutical Business in China
• Development of Novel Proteins, Biosimilars & Biobetters
• Cell Line Engineering & Development
• Cell Culture & Media Development
• Analytical Methods
• Comparability & Product Characterization
• Downstream Purification & Recovery
• Process Characterization, Validation & Quality Control
• Disposables
• Protein Stability & Formulation

Simultaneous translation will be available for the entire conference

With the huge potential for biopharmaceuticals in China, international companies are eager to get into the Chinese market. However, concerns over IP, regulatory, GMP and quality standards, skills and capabilities are holding them back. On the other hand, Chinese companies interested in working with international companies or to enter the international markets, are equally constrained by the lack of technical know-how, regulatory standards or the lack there-of, as well as need to source for the right partners and investors to help bring their skill-sets and business to the next level.

IBC's 2nd Annual BioProcess International™ China addresses these industry trends and brings forth experts in the respective areas to share valuable case studies, global approaches and key lessons learned. If you are working in the bioprocessing field or looking to enter, this is the one event held in China that will allow you to uncover China's untapped potential!

Domestic biosimilars have been on the market in China for 20 years. The first recombinant human interferon 1b was launched in 1989. Many of the international innovator drugs are already on the market in China, including Herceptin from Roche/Genentech and Humira from Abbott.

Despite the large market for biopharmaceuticals in China, there is no specific process for biosimilar approval. Due to the relatively low entry barrier, there are now over 400 biopharmaceutical companies producing over 2000 drugs, among them are over 20 producers of interferon and more than a dozen EPO manufacturers.

Although most of the Chinese drug developers are targeted at domestic market, a number of firms are setting their sights on international markets, and are starting to work towards WHO/ICH standards.